Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) FCF Margin (2016 - 2025)

Historic FCF Margin for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to 57.96%.

  • Ultragenyx Pharmaceutical's FCF Margin fell 87800.0% to 57.96% in Q3 2025 from the same period last year, while for Sep 2025 it was 71.58%, marking a year-over-year increase of 101100.0%. This contributed to the annual value of 75.27% for FY2024, which is 442600.0% up from last year.
  • As of Q3 2025, Ultragenyx Pharmaceutical's FCF Margin stood at 57.96%, which was down 87800.0% from 66.36% recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's FCF Margin ranged from a high of 48.62% in Q4 2024 and a low of 187.28% during Q1 2022
  • Moreover, its 5-year median value for FCF Margin was 113.51% (2022), whereas its average is 109.49%.
  • Data for Ultragenyx Pharmaceutical's FCF Margin shows a peak YoY increase of 1240500bps (in 2021) and a maximum YoY decrease of -2331600bps (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows Ultragenyx Pharmaceutical's FCF Margin stood at 84.41% in 2021, then crashed by -34bps to 113.51% in 2022, then surged by 41bps to 67.12% in 2023, then grew by 28bps to 48.62% in 2024, then decreased by -19bps to 57.96% in 2025.
  • Its FCF Margin stands at 57.96% for Q3 2025, versus 66.36% for Q2 2025 and 120.64% for Q1 2025.